On June 5, BeiGene fell 3.1% in regular trading, trading at HKD 162.6/share, with trading volume of HKD 550 million. The decline marks the stock's continued slide this week, pressured by both company-specific and sector-wide headwinds.

On the news front, Baker Bros. Advisors LP, a major shareholder affiliated with board members, recently reduced its position by approximately USD 190 million. While the fund retains its board seat and still holds around 8.21% of shares, the sizable reduction has persistently weighed on market sentiment. Additionally, the Hong Kong-listed innovative drug sector has been in a correction for over eight months since last September, with the sector benchmark index declining more than 30% over that period.

Within the Biotechnology sector, the overall tone remained weak. Among peers, AKESO fell 4.17%, REMEGEN fell 2.56%, 3SBIO fell 1.94%, and INNOVENT BIO fell 0.2%, while SKB BIO edged up 0.21%. As a heavyweight leader in the sector, BeiGene continues to be dragged by broad-based selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)